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1 These authors contributed equally to this work.Increasing evidence indicates that beta-amyloid (Ab) oligomers rather than monomers or ﬁbrils are
themajor toxic agents that speciﬁcally inhibit synaptic plasticity and long-term potentiation (LTP) in
Alzheimer’s disease (AD). Neutralization of Ab oligomeric toxicity was found to reverse memory def-
icits. Here, we report four single-chain variable fragment (scFv) antibodies isolated from the naive
human scFv library by phage display that speciﬁcally recognized Ab oligomers but not monomers
and ﬁbrils. These conformation-dependent scFv antibodies inhibit both Ab ﬁbrillation and cytotoxic-
ity and bind to the same type of eptitope displayed on the Ab oligomers. Such scFv antibodies specif-
ically targeting toxic Ab oligomersmay have potential therapeutic and diagnostic applications for AD.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction effective therapeutics to interfere with Ab oligomers formationThe previous prevailing beta-amyloid (Ab) ﬁbril-centered views
of Alzheimer’s diseases (AD) are altered and intensiﬁed efforts are
directed to investigate early aggregates because of the poor corre-
lation between the extent of Ab ﬁbril formation and the severity of
AD. Moreover, accumulating evidence suggests that soluble Ab
oligomers and protoﬁbrils but not mature ﬁbrils are the pivotal
toxins in AD progression [1,2]. Recent studies indicated that solu-
ble Ab dimers, trimers, amyloid b-derived diffusible ligands (ADD-
Ls), globular Ab oligomers and 56 kDa Ab assemblies inhibited LTP
and disrupt learned behave [3–6]. Regardless of which types of sol-
uble Ab oligomers are disrupting cognitive function, preventing
them from accumulating by inhibiting their oligomerization, pro-
moting their clearance or reducing monomer production are all ra-
tional therapeutic goals. Conformational antibodies may providechemical Societies. Published by E
myloid peptide; scFv, single-
onance; SDS–PAGE, sodium
LDH, lactate dehydrogenase;
olium bromide; ADDL, amy-and clearance with less side-effects. However, the development
of oligomer speciﬁc antibodies is very difﬁcult as oligomer deﬁni-
tion, purity and stability are not well deﬁned.
Both Ab active and passive immunization of transgenic mice
have been suggested as promising therapeutic strategies for the
treatment of AD as they can reduce amyloid load and reverse mem-
ory deﬁcits in these mice [7]. However, a clinical trial of immuniza-
tion with synthetic Abwas halted due to an unacceptable incidence
of meningoencephalitic reactions, presumably induced by T cell-
and/or Fc-mediated immune responses [8]. Here we show that con-
formation-dependent single-chain variable fragment (scFv) anti-
bodies without Fc fragments represent an attractive alternative to
more conventional antibody-based therapeutics to speciﬁcally rec-
ognize Ab oilgomers and reduce their toxicity.
2. Materials and methods
2.1. Materials
The following primary antibodies were used: 4G8 (monoclonal
raised against Ab17-24, Signet Laboratories), 16E9 (monoclonal
raised against Ab5-16, Santa Cruz), 9E10 (monoclonal raised
against scFv, Santa Cruz), A11 (rabbit polyclonal raised againstlsevier B.V. All rights reserved.
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blies, a gift from W. Klein (Department of Neurobiology and Phys-
iology, Northern University, IL, USA), R6 (rabbit polyclonal raised
against Ab1-16, produced in our laboratory).
The naive human scFv phage library (Tomlinson I and J phage
libraries), helper phage KM13, Escherichia coli TG1 and HB2151
were obtained from MRC Center for Protein Engineering (Cam-
bridge, England). Ab42 was purchased from American Peptide
Company (Sunnyvale, CA, USA) and the Ab42 oligomers and ﬁbrils
were prepared as previously described with some modiﬁcations
[9]. Brieﬂy, Ab42 was dissolved in 100% 1,1,1,3,3,3-hexaﬂuoro-2-
propanal (HFIP) to a concentration of 1 mg/mL, sonicated in a
water bath for 10 min, aliquoted into microcentrifuge tubes, dried
under vacuum, and stored at 20 C. Immediately prior to use, the
HFIP-treated Ab42 was dissolved in dimethylsulfoxide (DMSO) to
1 mg/mL and diluted to 10 lM in PBS, pH 7.4 and incubated at
37 C. For Ab42 oligomer preparation, the 12 h incubation samples
were centrifuged for 15 min at 14000g and the supernatant frac-
tion containing oligomers was checked by AFM. For Ab42 ﬁbril
preparation, the four d incubation samples were centrifuged for
15 min at 14000g and the ﬁbril pellet was washed three times
with PBS and then checked by AFM. ADDLs were prepared as pre-
viously described [10].2.2. Bio-panning using the phage display library
ScFv selection was performed using four rounds of panning
essentially as described previously with slight modiﬁcations [11].
Brieﬂy, high binding 96-well plates (Corning, USA) were coated
with 1 lg/well of Ab42 oligomers overnight at 4 C. Plates were
blocked with 2% milk powder in PBS for at least 2 h at room tem-
perature. An aliquot of 1012 phage units from the naive library was
incubated with the peptide. Plates were thoroughly washed with
PBS, pH 7.4, plus 0.1% Tween-20 solution to remove any unbound
phage. Bound phages were eluted with trypsin in PBS. Eluted
phages were subsequently ampliﬁed by infecting E. coli TG1 in
the presence of helper phage KM13. The phages were further puri-
ﬁed using polyethylene glycol (MW 6000)/NaCl precipitation and
resuspended in PBS and used for further rounds of selection.2.3. Screening of positive clones and puriﬁcation of scFv’s
Eluted phages from the fourth round of selection were used to
infect E. coli HB2151. Individual clones were grown in 96-well
plates and scFv expression was induced by adding 1 mM isopropyl
b-D-thiogalactoside (IPTG). The ELISA for screening of positive
clones with supernatant was carried out as described previously
[11]. Clones showing the higher absorbance based on ELISA were
selected for further studies.
The presence of a scFv gene insert in a plasmid isolated from the
selected clone was conﬁrmed by PCR ampliﬁcation and sequencing
as described previously [11]. Production and puriﬁcation of scFv
were performed as indicated previously [12]. The purity and
molecular mass of scFv’s was estimated by electrophoresis on
12% (w/v) SDS–polyacrylamide gels.2.4. Western-blot and dot-blot
For detection of scFv’s, the puriﬁed scFv’s were loaded on 12%
SDS–PAGE and transferred to a nitrocellulose membrane. ScFv
was immunodetected using HRP-conjugated anti-myc 9E10 anti-
body and DAB. To investigate the binding of scFv’s to Ab42 oligo-
mers, Ab42 incubated for 21 h at 37 C was loaded onto 16.5%
Tris–tricine SDS gels. The gels were transferred to PVDF mem-branes (0.2 lM) and the membranes were blocked, washed and
incubated with 4G8 or W8 antibody. The membrane was washed
again and incubated with HRP-conjugated anti-mouse lgG or
HRP-conjugated 9E10. The blots were developed with the ECL
chemiluminescence kit (Pierce, Rockford, IL, USA). For dot-blot,
samples were applied to nitrocellulose membrane. The membrane
was blocked and then incubated with primary antibody. The bound
antibody was probed by HRP-conjugated Protein A. Immunoreac-
tive signals were visualized with DAB.
2.5. BIAcore study
Antigen-scFv binding was performed using a BIAcore X biosen-
sor (BIAcore Inc., Uppsala, Sweden) as described previously [11].
The concentrations of scFv’s diluted serially which were applied
to the Biacore were between 0.5 lM and 4.5 lM.
2.6. Thioﬂavin T (ThT) ﬂuorescence assay
The extent of Ab ﬁbrillation in the samples was followed by
periodically removing 20 ll of the incubated samples and adding
them to 2 mL of 5 lM ThT solution (50 mM phosphate buffer, pH
6.5). Fluorescence intensity was monitored at an excitation wave-
length of 450 nm and an emission wavelength of 482 nm using a
Tecan Saﬁre 2 microplate reader (Tecan, Switzerland). All ThT ﬂuo-
rescence experiments were performed in triplicate.
2.7. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) and DHL assay
Cell culture, MTT and lactate dehydrogenase (LDH) assay were
performed as described previously with light modiﬁcations [12–
14]. Human neuroblastoma cells (SH-SY5Y) were used and ali-
quoted into 96-well plates (Corning) at approximately 104 cells
per well in 100 lL of medium and incubated for 24 h to allow
attachment to the bottom of the wells. Different samples were
added and incubated for additional 48 h, MTT was added to each
well. The plates were incubated for 3 h at 37 C, and then a
100 lL aliquot of MTT crystal dissolvent (10% SDS and 5% isobuta-
nol in 0.01 N HCl) was added. Plates were put at 37 C overnight to
dissolve crystals. The absorbance at 560 nm was measured by Te-
can Saﬁre 2 microplate reader (Tecan, Switzerland). LDH release
was measured using an LDH release toxicity kit (Sigma, St. Louis,
MO, USA) as described in the protocol provided by the
manufacturer.3. Results
3.1. Biopanning against Ab oligomers
Phage screening was performed using four rounds of panning
processes. Individual positive clones were selected by ELISA. Se-
lected clones were analyzed further by PCR and nucleic acid
sequencing. The results showed that 4 scFv’s positive clones
(termed W8, W9, W20, and WC2) contain full CDR and frame re-
gions and the variability of amino acid residues of 4 scFv’s are pri-
marily located within the CDR2 and CDR3 region of the heavy and
light chain (data not shown). Plasmid DNA from the positive clones
was isolated and transformed into the non-suppressor E. coli strain
HB2151 for production of soluble scFv. Four scFv’s were puriﬁed
using a protein A column. The eluted fractions were analyzed by
SDS–PAGE on a 12% polyacrylamide gel and also by Western-blot
using anti-myc 9E10. Puriﬁed protein showed a single protein band
with molecular mass of 29 kDa, corresponding to expression of a
full-length scFv (Fig. 1A and B).
Fig. 1. Western-blot analyses of puriﬁed scFv antibodies and characterization of
binding of scFv’s to Ab oligomers. (A) SDS–PAGE analyses of scFv antibodies puriﬁed
from protein A afﬁnity column. (B) ScFv antibodies were transferred to nitrocel-
lulose membrane and probed with 9E10 antibody. Bound antibodies were detected
using a HRP-conjugated goat anti-mouse and visualized with DAB. (C) Aggregation
of Ab42 was monitored by dot-blot. Aliquots of samples were applied to
nitrocellulose membrane (0.12 lg/dot) at the time indicated and then probed with
4G8 and scFv antibodies, respectively. Bound antibodies were detected with HRP-
conjugated Protein A and visualized with DAB (D) Ab42 monomers, oligomers and
ﬁbrils were spotted to nitrocellulose membrane (0.5 lg/dot) and were probed and
visualized as (C). (E) Ab42 oligomers and ADDLs were spotted to nitrocellulose
membrane and probed with A11, 4G8 and scFv’s and then visualized as (C). (F)
Determination of scFv antibodies binding to Ab42 aggregates by Western-blot. It
was performed as indicated in Section 2 and visualized with ECL chemilumines-
cence kit.
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The speciﬁc binding of scFv’s to Ab42 oligomers was validated
by dot-blot and Western-blot (Fig. 1C–F). Ab42 oligomer formation
started in a few minutes and it was time-dependent [10]. At zero
point, scFv’s did not bind to nitrocellulose as only Ab42 monomers
but no oligomers presented in the samples. After 1 or 10 min, some
oligomers were assembled and the dot-blot showed light staining.
Over the next 20 min, oligomerization was relatively rapid, and the
dot-blot showed denser staining (Fig. 1C). Four scFv’s speciﬁcally
bound to Ab42 oligomers, but not monomers and ﬁbrils (Fig. 1D).
However, 4G8, as a control, bound to all three types of Ab42. The
binding of scFv’s to ADDLs was also assayed by dot-blot with
A11 as a control. Four scFv’s and A11 all could bind to both ADDLs
and oligomers, but the dot-blot by immunoreaction of A11 with
oligomers showed light staining (Fig. 1E). In harmony with above
dot-blot results, the results of Western-blot using Ab aggregatesshowed that 4G8 could bind to all types of Ab42. However, scFv’s
did not bind to Ab monomers and ﬁbrils, but only bond to Ab tri-
mers, tetramers and little bigger oligomers (Fig. 1F). Furthermore,
our ELISA results indicated that 4 scFv antibodies did not bind to
short Ab fragments, Ab1-16, 17-28 and 29-42 (data not shown).
In conclusion, 4 scFv’s isolated from scFv library speciﬁcally bind
to Ab42 oligomers, but not Ab42 monomers, shorter Ab42 frag-
ments and ﬁbrils.
3.3. Binding kinetics of scFv’s to Ab oligomers
Surface plasmon resonance (SPR) binding studies were per-
formed using a BIAcore X biosensor. Ab oligomers were immobi-
lized onto an activated CM5 sensor chip. W8, W9, W20, WC2 and
a control scFv were serially diluted and injected over the chip. Data
collected represent the value of the observed response units (RU)
obtained in the sample cells minus the RU obtained from a refer-
ence cell. The association (ka) and dissociation (kd) rate constants
and the dissociation constants (KD = ka/kd) for the scFv’s were
evaluated using BIA evaluation 3.1 software (BIAcore Inc., Uppsala,
Sweden). For W8, W9, W20, and WC2, ka are 4.02  103,
4.86, 2.91  103 and 4.29  102 M1 s1, kd are 3.08  105,
2.39  105, 1.74  105 and 1.74  105 s1, KD are 7.66  108,
4.91  106, 5.99  109 and 3.32  107 M, respectively, indicat-
ing that W8 and W20 have higher afﬁnity to Ab oligomers than
W9 and WC2, primarily due to differences in the association rate
constant, ka, rather than in the dissociation rate constant, kd.
3.4. ScFv’s inhibit Ab ﬁbrillation
We assessed the ability of scFv’s to inhibit Ab42 ﬁbrillation
using the ThT binding assay. When incubated alone, Ab42 showed
the expected time-dependent increase in ﬂuorescence, reaching a
plateau value after approximately 28 h. When 10 lM Ab42 co-
incubated with 0.1, 0.25 and 1 lM of W20, Ab42 ﬁbrillation was
strongly inhibited in a dose-dependent manner (Fig. 2A). At the
highest concentration of W20 (1 lM), around 80% inhibition of
ﬁbrillation was observed. W8, W9 and WC2 also showed the sim-
ilar ability to inhibit ﬁbrillation of Ab42 sample, while WC2 had
smaller effects on Ab42 ﬁbrillation when the same concentrations
of scFv’s were used (Fig. 2B). To study the ability of 4 scFv’s to dis-
solve preformed amyloid aggregates, 1 lM of different scFv’s were
added to a 28 h preincubated sample of Ab42 respectively. ScFv’s
dramatically decrease the ﬂuorescence intensity of the preformed
Ab42 aggregates after their co-incubation for 24 h and 48 h
(Fig. 2C).
3.5. ScFv’s block cytotoxicity of Ab oligomers
We determined the cytotoxicity of the Ab42 samples in the
presence or absence of scFv’s toward SH-SY5Y cells. Cells treated
with aliquots of Ab42 incubated alone for 0 or 21 h showed re-
duced MTT activity and higher LDH release compared to the con-
trol wells, indicating the earlier aggregate morphologies of Ab42
are toxic to the cells (Fig. 3). However, cells treated with an aliquot
of Ab42 incubated for 48 h showed little or no toxicity in both MTT
and LDH assays, indicating the later aggregate morphologies ob-
served here are non-toxic to the cells. Addition of four scFv’s
blocked any Ab42-induced toxicity at the 0 and 21 h time points.
These results are consistent with many previous studies that iden-
tiﬁed the soluble oligomeric Ab42 forms as the toxic species
responsible for neuronal cell death and the inhibition of toxicity
by antibodies [3–6]. Although there are no Ab42 oligomers present
in the samples of Ab42 alone and Ab42 with scFv’s at 0 time point
(Fig. 1C), Ab42 oligomers may be formed during the process of 48 h
incubation for toxicity assay and decreased the cell viability and
Fig. 2. Effects of scFv antibodies on ﬁbrillation of Ab42. (A) The kinetics of 10 lM
Ab42 ﬁbril formation was monitored by ThT ﬂuorescence in the absence or
presence of W20 at different concentrations, respectively. The experiment was
performed as indicated in Materials and methods section. (B) Effects of W8, W9,
WC2 on ﬁbrillation of Ab42. ThT ﬂuorescence was measured after 28 h incubation
of 10 lM Ab42 in the absence or presence of scFv’s. (C) Disaggregation of preformed
Ab42 aggregates by scFv antibodies. The ThT ﬂuorescence was measured after
10 lM preformed Ab42 aggregates were incubated with or without 1 lM scFv
antibodies for 24 and 48 h.
Fig. 3. Effects of scFv antibodies on Ab42-induced cytotoxicity. Aliquots of Ab42
preincubated with or without scFv’s at indicated times were added to wells coated
with SH-SY5Y cells. The ﬁnal concentration of both Ab42 and scFv was 1 lM. After
an additional two-day incubation of cells and samples, the viability of the cells was
measured using both MTT toxicity assay (A) and LDH release assay (B). Statistical
analysis was carried out using one-way ANOVA (Prism software) followed by
Bonferroni test for multiple comparisons (*P < 0.05, **P < 0.01).
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although KD values of scFv’s are robust different, four scFv antibod-
ies showed similar inhibitory effect on Ab42 aggregation and cyto-
toxicity, which may result from their similar dissociation rate
constants, kd. Once scFv’s bind to Ab42 oligomers, they may disso-
ciate at similar rates.
3.6. Analyses of epitopes displayed on Ab oligomers
To investigate the relationships of epitopes recognized by dif-
ferent antibodies, we evaluated the competitive binding activityof W20 with Ab42 oligomers in the presence of W8, W9, WC2,
4G8, NU1 and A11, respectively. The results showed that W8, W9
and WC2 but not 4G8, NU1 and A11 competed signiﬁcantly with
W20 to bind to the oligomers (Fig. 4), suggesting that W8, W9,
W20 andWC2 may bind to the same epitope displayed on the olig-
omers, but they do not bind to the epitopes recognized by oligomer
speciﬁc polyclonal antibody A11 and anti-Ab assemblies (including
oligomers and ﬁbrils) antibody NU1 [10], indicating that our scFv’s
and A11 or NU1 may bind different oligomeric epitopes.
4. Discussion
The differences of conformation and characterization among
monomers, oligomers, and ﬁbrils hint existence of distinct epitopes
on their molecules, providing bases to develop conformation-
dependent antibodies [15,16]. Our dot-blot and Western-blot re-
sults showed that four scFv’s speciﬁcally bind to conformational
epitopes formed by Ab oligomerization which do not exist on the
Ab monomers and ﬁbrils. The competing ELISA results indicated
that 4 scFv’s bind to the same epitope and such these scFv’s and
A11 or NU1 bind to different epitopes displayed on the Ab
Fig. 4. Analyses of epitopes displayed on Ab42 oligomers. Ab oligomers were
incubated with or without serially diluted antibodies W8, W9, WC20, 4G8, NU1 and
A11 for 1 h at 37 C and then added to high afﬁnity microtiter plates coated with
W20. The captured Ab oligomers were detected by 16E9. Bound 16E9 was further
detected by HRP-conjugated goat anti-mouse antibody. Relative OD values were
calculated by dividing the OD of Ab oligomers with competing antibodies by the OD
of Ab oligomers alone.
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mer speciﬁc epitopes formed during the oligomerization. Our dot-
blot, ThT staining and cytotoxicity assay results showed that scFv’s
could not only bind to ADDLs and Ab oligomers but also inhibit Ab
ﬁbrillation and cytotoxicity, which is consistent with previous re-
port that binding to some oligomeric epitopes with speciﬁc anti-
bodies may neutralize the toxicity of oligomers [9].
Selected scFv’s can distinguish toxic Ab oligomers from mono-
mers and ﬁbrils, indicating that they may be used in the ﬁelds of
diagnosis, the measurement of the oligomer species and the treat-
ment for AD. Such speciﬁc scFv antibodies recognizing and inacti-
vating a conformational epitope could be superior for AD
treatment and be less prone to initiating an autoimmune inﬂam-
matory response because the oligomer epitope occurs only in mis-
folded protein structures speciﬁc to pathological states. Moreover,
compared to full conventional antibodies, scFv’s do not include the
Fc portion and therefore they cannot initiate the complement cas-
cade and limit the inﬂammatory response upon binding to Ab olig-
omers. ScFv’s are readily available for genetic manipulations, large-
scale expression and detailed functional analysis. In addition, the
scFv’s are much smaller than conventional antibodies and can be
easily modiﬁed to facilitate transport across the blood–brain bar-
rier. As a kind of monoclonal antibody, scFv has an advantage to
be used to determine the amino acid components and the structure
of the epitope. It is tempting to characterize the conformational
epitopes of oligomers, as a known epitope can be used as templates
for design of vaccine immunogens and as targets for inhibitors.
Here, the oligomer speciﬁc scFv’s offer tools for development of
vaccines, inhibitors and research reagents.
The isolated scFv’s here are similar to our previous scFv (H1V2)
against Ab40 monomer in their ability to inhibit Ab aggregation
and cytotoxicity [11]. Moreover, we have conﬁrmed that our pres-
ent scFv antibodies also speciﬁcally bound to Ab40 oligomers and
H1V2 bound to Ab42 monomer. Two types of scFv’s may interfere
with the aggregation and cytotoxicity of both Ab40 and Ab42
simultaneously, which warrants further study. Additionally, we
tested the ability of our scFv antibodies to bind to oligomers of
amylin and Prion protein fragments 106–126. The results showed
that W8 and W20 did not recognize the epitopes displayed on
the oligomers of these proteins, which is different from the previ-ous anti-oligomer antibody studies that rabbit polyclonal antibod-
ies A11 with broader speciﬁcity could reacted with oligomeric
aggregate forms from numerous different proteins. Consistent with
the rabbit polyclonal antibody M93 raised against ADDLs, our pres-
ent scFv’s could also speciﬁcally bind to ADDLs [17,18]. Recent re-
ports showed that novel camelid single-chain binding domains
(VHHs) speciﬁcally bound to Ab oligomers and prevented Ab-in-
duced neurotoxicity [19,20]. But their direct applications in the
treatment for AD may be limited because the antibodies from a
camelid or other origins, such as rabbits or mice, may induce aller-
gic reactions. The previous studies reported that mouse anti-
assembly antibodies NU1 and NAB61 with broader speciﬁcity
could react with both oligomer and ﬁbril forms [10,21]. However,
the smaller oligomer speciﬁc scFv antibodies selected from the na-
ive human scFv phage library described here target only to Ab olig-
omers and may have potential applications in AD treatment and
speciﬁcally identifying and evaluating the level of toxic Ab oligo-
mer states in samples.Acknowledgments
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